Adial Pharmaceuticals (ADIL) Competitors

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

$2.17

-0.15 (-6.47%)

(As of 04/18/2024 ET)

ADIL vs. AKTX, BFRI, MTEM, GRTX, LGVN, HEPA, VIRI, AEZS, ATHE, and CYCN

Should you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Akari Therapeutics (AKTX), Biofrontera (BFRI), Molecular Templates (MTEM), Galera Therapeutics (GRTX), Longeveron (LGVN), Hepion Pharmaceuticals (HEPA), Virios Therapeutics (VIRI), Aeterna Zentaris (AEZS), Alterity Therapeutics (ATHE), and Cyclerion Therapeutics (CYCN). These companies are all part of the "pharmaceutical preparations" industry.

Adial Pharmaceuticals vs.

Adial Pharmaceuticals (NASDAQ:ADIL) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment.

: 16.4% of Adial Pharmaceuticals shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 14.5% of Adial Pharmaceuticals shares are held by insiders. Comparatively, 61.8% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adial Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Akari Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: In the previous week, Akari Therapeutics had 5 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 5 mentions for Akari Therapeutics and 0 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.98 beat Akari Therapeutics' score of 0.28 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.
Company Overall Sentiment
Adial Pharmaceuticals Positive
Akari Therapeutics Neutral
: Akari Therapeutics' return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Adial Pharmaceuticals N/A -250.52% -183.24%
Akari Therapeutics N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Adial Pharmaceuticals N/A N/A -$5.12M -$5.72 -0.38
Akari Therapeutics N/A N/A -$10.01M N/A N/A
: Adial Pharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Akari Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
: Akari Therapeutics received 154 more outperform votes than Adial Pharmaceuticals when rated by MarketBeat users. However, 58.06% of users gave Adial Pharmaceuticals an outperform vote while only 55.04% of users gave Akari Therapeutics an outperform vote.
Company Underperform Outperform
Adial Pharmaceuticals Outperform Votes
108
58.06%
Underperform Votes
78
41.94%
Akari Therapeutics Outperform Votes
262
55.04%
Underperform Votes
214
44.96%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Akari Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Overall Sentiment
Adial Pharmaceuticals	Positive
Akari Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-250.52%	-183.24%
Akari Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$5.12M	-$5.72	-0.38
Akari Therapeutics	N/A	N/A	-$10.01M	N/A	N/A

Company	Underperform	Outperform
Adial Pharmaceuticals	Outperform Votes 108 58.06%	Underperform Votes 78 41.94%
Akari Therapeutics	Outperform Votes 262 55.04%	Underperform Votes 214 44.96%

Summary

Adial Pharmaceuticals and Akari Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Get Adial Pharmaceuticals News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADIL vs. The Competition

Export to Excel

Metric	Adial Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.79M	$6.45B	$4.77B	$7.44B
Dividend Yield	N/A	2.97%	3.00%	4.00%
P/E Ratio	-0.38	17.71	254.51	19.15
Price / Sales	N/A	330.89	2,420.87	85.86
Price / Cash	N/A	20.94	47.48	35.12
Price / Book	0.88	5.48	4.59	4.19
Net Income	-$5.12M	$147.46M	$104.46M	$214.15M
7 Day Performance	-27.18%	-7.89%	-5.35%	-4.91%
1 Month Performance	33.13%	-7.77%	-4.82%	-3.49%
1 Year Performance	-71.74%	-3.66%	8.55%	3.83%

Adial Pharmaceuticals Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKTX Akari Therapeutics	0 of 5 stars	$1.16 -3.3%	N/A	-69.4%	$9.19M	N/A	0.00	15	Analyst Report
BFRI Biofrontera	2.3527 of 5 stars	$1.81 +10.4%	$18.00 +894.5%	-85.6%	$9.21M	$34.07M	-0.11	83	Positive News
MTEM Molecular Templates	1.3791 of 5 stars	$1.66 -6.7%	N/A	-78.5%	$8.91M	$57.31M	-1.07	111
GRTX Galera Therapeutics	0 of 5 stars	$0.17 +13.3%	N/A	-92.9%	$9.25M	N/A	-0.12	31	Gap Up
LGVN Longeveron	2.9972 of 5 stars	$3.53 +20.5%	$60.00 +1,599.7%	-92.4%	$8.86M	$710,000.00	-0.35	23	High Trading Volume
HEPA Hepion Pharmaceuticals	0.197 of 5 stars	$2.04 -6.4%	N/A	-86.5%	$8.85M	N/A	0.00	25	Short Interest ↑
VIRI Virios Therapeutics	0.1133 of 5 stars	$0.45 -4.3%	N/A	-31.0%	$8.62M	N/A	-1.60	4	Gap Down
AEZS Aeterna Zentaris	1.6957 of 5 stars	$1.96 flat	$15.00 +665.3%	-28.0%	$9.53M	$4.50M	-0.57	11
ATHE Alterity Therapeutics	3.6372 of 5 stars	$2.05 -16.3%	$7.00 +241.5%	-28.4%	$9.57M	$3.37M	0.00	11	High Trading Volume
CYCN Cyclerion Therapeutics	0 of 5 stars	$3.15 -5.1%	N/A	-52.7%	$8.54M	$1.62M	-0.57	1	Short Interest ↓ News Coverage Positive News

Related Companies and Tools

Related Companies:

Top 10 Stock Comparisons

This page (NASDAQ:ADIL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. AKTX, BFRI, MTEM, GRTX, LGVN, HEPA, VIRI, AEZS, ATHE, and CYCN

Adial Pharmaceuticals vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info